KalVista Pharmaceuticals (KALV) Non Operating Income (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Non Operating Income of $818000.0 in Q3 2025, up 169.2% quarter-over-quarter from -$1.2 million in Q2 2025, and down 47.77% year-over-year from $1.6 million in Q3 2024.
KalVista Pharmaceuticals' Non Operating Income history runs 12 years deep, the most recent figure standing at $818000.0 for Q3 2025.
- In Q3 2025, Non Operating Income fell 47.77% year-over-year to $818000.0; the TTM figure through Jul 2025 stood at $3.3 million (down 56.05% YoY), while the FY2025 annual figure was $4.8 million, down 50.73% from the prior year.
- Non Operating Income came in at $818000.0 for Q3 2025 at KalVista Pharmaceuticals, up from -$1.2 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $6.6 million in Q2 2023 to a low of -$1.2 million in Q2 2025.
- A 5-year average of $2.7 million and a median of $2.9 million in 2021 frame the typical range for Non Operating Income.
- Across the five-year window, Non Operating Income soared 92.26% in 2023 and sank 418.42% in 2025, its largest moves.
- KalVista Pharmaceuticals' Non Operating Income stood at $3.9 million in 2021, then dropped by 8.04% to $3.6 million in 2022, then sank by 42.2% to $2.1 million in 2023, then advanced by 1.1% to $2.1 million in 2024, then tumbled by 61.4% to $818000.0 in 2025.
- According to Business Quant data, Non Operating Income over the past three periods registered $818000.0, -$1.2 million, and $2.1 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 818,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 818,000.00 |
| Apr 30, 2025 | -1.18 Mn |
| Oct 31, 2024 | 2.12 Mn |
| Jul 31, 2024 | 1.57 Mn |
| Apr 30, 2024 | -228,000.00 |
| Jan 31, 2024 | 4.12 Mn |
| Oct 31, 2023 | 2.10 Mn |
| Jul 31, 2023 | 2.40 Mn |
| Apr 30, 2023 | 6.61 Mn |
| Jan 31, 2023 | 4.31 Mn |
| Oct 31, 2022 | 3.63 Mn |
| Jul 31, 2022 | 3.55 Mn |
| Apr 30, 2022 | 3.44 Mn |
| Jan 31, 2022 | 4.16 Mn |
| Oct 31, 2021 | 3.94 Mn |
| Jul 31, 2021 | 3.18 Mn |
| Apr 30, 2021 | 2.64 Mn |
| Jan 31, 2021 | 2.17 Mn |
| Oct 31, 2020 | 2.36 Mn |
| Jul 31, 2020 | 2.93 Mn |
| Apr 30, 2020 | 2.50 Mn |
| Jan 31, 2020 | 2.92 Mn |
| Oct 31, 2019 | 3.39 Mn |
| Jul 31, 2019 | 2.09 Mn |
| Apr 30, 2019 | 2.86 Mn |
| Jan 31, 2019 | 1.73 Mn |
| Oct 31, 2018 | 1.59 Mn |
| Jul 31, 2018 | 1.82 Mn |
| Apr 30, 2018 | 2.31 Mn |
| Jan 31, 2018 | 985,000.00 |
| Oct 31, 2017 | 951,000.00 |
| Jul 31, 2017 | 555,000.00 |
| Apr 30, 2017 | 2.43 Mn |
| Jan 31, 2017 | 473,000.00 |
| Oct 31, 2016 | 368,000.00 |
| Jul 31, 2016 | 275,000.00 |
| Mar 31, 2016 | -3,000.00 |
| Dec 31, 2015 | -4.36 Mn |
| Sep 30, 2015 | 1,000.00 |
| Jun 30, 2015 | -1,000.00 |
| Mar 31, 2015 | 553,000.00 |
| Sep 30, 2014 | -71,000.00 |
| Jun 30, 2014 | -199,000.00 |
| Mar 31, 2014 | -159,000.00 |